论文部分内容阅读
目的:建立骨髓生长因子药物利用评价标准(Drug Use Evaluation,DUE),并应用于分析骨髓生长因子临床使用的合理性。方法:采用“AGREEⅡ临床实践指南评估系统”筛选A级推荐的指南,根据A级推荐指南,构建骨髓生长因子DUE标准基本框架。结合新编药物学和药品说明书等,组织专家讨论并建立骨髓生长因子DUE标准。回顾性分析某三甲医院300例骨髓生长因子使用情况。结果:建立的骨髓生长因子评价标准主要包括用药适应证、用药方案、用药结果,血常规监测4个方面,应用结果显示某三甲医院使用骨髓生长因子的不合理现象主要表现为适应证、血常规监测、用药疗程、用法用量不合理。不合理率分别为20.67%,35.33%,28.33%,29.00%。结论:建立的骨髓生长因子DUE评价标准具有较好的应用性,实用性强,且易操作,可发现临床用药存在的问题和不足。
Objective: To establish the Drug Use Evaluation (DUE) and to analyze the rationality of clinical application of bone marrow growth factor. Methods: A grade A recommended guidelines were screened using the “AGREE Ⅱ Clinical Practice Guidelines Assessment System”, and the basic framework of bone marrow growth factor DUE standard was constructed according to the A grade recommendation guideline. Combined with the new pharmacy and drug manuals, organize experts to discuss and establish the standard bone marrow growth factor DUE. A retrospective analysis of 300 cases of bone marrow in a top three hospital use of bone marrow growth factor. Results: The evaluation criteria of myeloid growth factor mainly included four aspects: drug indications, medication regimen, medication results and blood routine monitoring. The results showed that the irrational use of bone marrow growth factor in a top three hospital mainly manifested as indications, blood routine Monitoring, medication, usage and dosage unreasonable. Unreasonable rates were 20.67%, 35.33%, 28.33%, 29.00% respectively. Conclusion: The establishment of bone marrow growth factor DUE evaluation criteria has good applicability, practicality, and easy to operate, we can find the problems and deficiencies of clinical medication.